Q BioMed Inc (QBIO)

[Robertscott]

$QBIO Company Overview
Q BioMed (QBIO) aims to accelerate the monetization of biomedical technologies through rapid
innovation and collaborative partnerships with industry leading researchers. Q BioMed launched its
FDA approved, non-opioid drug Strontium89 (strontium chloride Sr-89 Injection, USP), which
relieves pain from metastatic cancer in the bone, in the U.S. in February 2020. Strontium89 is
Medicare/payor reimbursed in the U.S. and is available outside the U.S. to a potential global
population of 10 million people through a Named Patient Program. Q BioMed’s clinical pipeline in
oncology, vascular disease, and rare orphan diseases addresses unmet medical needs in large
markets and is expected to produce substantial revenues for the Company and value inflection
points for investors for years to come.